Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...